We chose a sequential, combined TMZ/AT101 strategy, since AT101 is an inhibitor of antiapoptotic Bcl-2 family proteins and induces cell death in tumor cells including GBMs [26–29]. The gene discussed is BCL2; the disease is neoplasm.